Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Blocking Insulin-degrading Enzyme Reverses Diabetes Symptoms in Mouse Model

By BiotechDaily International staff writers
Posted on 15 Jun 2014
Image: Molecular model shows how the inhibitor binds to Insulin Degrading Enzyme (IDE). The inhibitor is depicted in orange and white spheres. IDE is depicted as the blue and green surface, and the gray ribbons (Photo courtesy of Dr. Markus Seeliger, Stony Brook University).
Image: Molecular model shows how the inhibitor binds to Insulin Degrading Enzyme (IDE). The inhibitor is depicted in orange and white spheres. IDE is depicted as the blue and green surface, and the gray ribbons (Photo courtesy of Dr. Markus Seeliger, Stony Brook University).
Determination of the structure of insulin-degrading enzyme (IDE) by X-ray crystallography paved the way for its successful inhibition and the easing of symptoms in a mouse model of type II diabetes.

The IDE gene encodes a zinc metallopeptidase that degrades intracellular insulin, and thereby terminates its activity, as well as participating in intercellular peptide signaling by degrading diverse peptides such as glucagon, amylin, bradykinin, and kallidin. The preferential affinity of this enzyme for insulin results in insulin-mediated inhibition of the degradation of other peptides such as beta-amyloid. Deficiencies in this protein's function are associated with Alzheimer's disease and type II diabetes mellitus but mutations in this gene have not been shown to be causative for these diseases. This protein localizes primarily to the cytoplasm but in some cell types localizes to the extracellular space, cell membrane, peroxisome, and mitochondrion.

Investigators at Stony Brook University (NY, USA) and colleagues at Harvard University (Cambridge, MA, USA) and Brookhaven National Laboratory (Upton, NY, USA) reported in the May 21, 2014, online edition of the journal Nature that they had discovered a physiologically active IDE inhibitor from a DNA-templated macrocycle library. An X-ray structure of the macrocycle bound to IDE revealed that it engaged a binding pocket away from the catalytic site, which explained its remarkable selectivity.

Treatment of lean and obese mice with this inhibitor showed that IDE regulated the abundance and signaling of glucagon and amylin, in addition to that of insulin. Under physiological conditions that increased insulin and amylin levels, such as oral glucose administration, acute IDE inhibition led to substantially improved glucose tolerance and slower gastric emptying.

"A strategy to protect the remaining amounts of insulin produced by diabetics in response to blood sugar levels is an attractive treatment alternative, particularly in the early stages of type II diabetes,” said contributing author Dr. Markus Seeliger, assistant professor of pharmacological sciences at Stony Brook University. “The research results give proof of concept that targeting this protein is extremely promising. The inhibitor we discovered successfully relieved the symptoms of type II diabetes in obese mice and not only elevated their insulin levels but promoted healthy insulin signaling within the blood.”

Related Links:

Stony Brook University
Harvard University
Brookhaven National Laboratory



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

21 Apr 2015 - 23 Apr 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.